EIN Presswire

Aviv Biomedical Announces the New Bilirubin Hematofluorometer Providing New Opportunities for Detection and Management of Neonatal Jaundice, A Global Unmet Clinical Need LAKEWOOD, NEW JERSEY, USA, January 11, 2018 /EINPresswire.com/ — Lakewood, New Jersey, 8 January 2018 – Aviv Biomedical (“Aviv”; www.avivbiomedical.com) announces the launch of a new initiative to…

Continue reading

Bilirubin Hematofluorometer Project Awarded Phase IIb Funding

Aviv Biomedical has been awarded a two year NIH Phase IIb SBIR grant (5R44TR001635-04 & 5R44TR001635-05) to make additional improvements, and prepare the Bilirubin Hematofluorometer for regulatory approval.  Aviv has already completed Phase I (proof-of-principle), and Phase II (successful commercialization) funding.  NIH SBIR Phase IIb funding is awarded to proven…

Continue reading